FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379984267> ?p ?o ?g. }

• W4379984267 endingPage "5462" @default.
• W4379984267 startingPage "5462" @default.
• W4379984267 abstract "Abstract Background: In AENEAS trial (NCT03849768), first-line Au for EGFR-mutated, advanced NSCLC showed robust improvement in PFS over gefitinib (G). CPK elevation was the most common AE during Au treatment which may pose safety concerns. To evaluate the relationship between CPK elevation and Au efficacy, we performed a post-hoc analysis of AENEAS. Methods: AENEAS is a double-blind, randomized controlled phase III trial. Untreated advanced NSCLC pts with EGFR sensitizing mutations were assigned 1:1 to receive Au (110 mg QD) or G (250 mg QD). The primary endpoint was PFS. Secondary endpoints included ORR, DCR, DoR and DepOR. Data cutoff: Aug 1, 2021. Results: 37.9% (81/214) of pts receiving Au had CPK elevation, among whom the mPFS was 26.3 mos and was significantly longer (HR=0.45; 95% CI: 0.31-0.67; P&lt;.0001) than that of the CPK-normal pts (133/214) at 13.9 mos. PFS benefits remained consistent across all prespecified subgroups. Also for all the secondary endpoints, CPK-elevated pts demonstrated significant benefits over CPK-normal pts (TABLE). Multivariable regression analysis revealed that CPK elevation was an independent predictor of prolonged PFS for pts receiving Au, with 54% reduced risk of progression or death for CPK-elevated pts compared with CPK-normal pts (HR=0.46; 95%CI: 0.31-0.68; P=.0001). Au demonstrated PFS benefits over G in both CPK-elevated pts (HR=0.40; 95% CI: 0.21-0.79; P=.0059) and CPK-normal pts (HR=0.63; 95% CI: 0.48-0.83; P=.0010), and the benefit was magnified in CPK-elevated pts. Further supported by post-hoc analysis of a phase 1/2 study (NCT02981108), PFS was also significantly prolonged in CPK-elevated pts receiving second or later line Au (17.7 vs 10.9 mos; HR=0.63; 95% CI: 0.46-0.87; P=.0049). Conclusion: Our study first revealed the predictive value of CPK elevation on improved treatment response of Au, which is of great significance to help guide medical care. Summary of Endpoints Elevated CPK(N=81) Normal CPK(N=133) PFS, months Median (95% CI) 26.3 (20.7-NA) 13.9 (12.4-19.8) HR (95% CI) 0.45 (0.31-0.67) P-value &lt;0.0001 12-months PFS rate (95% CI) 84.9 (74.9-91.1) 59.4 (50.2-67.5) 24-months PFS rate (95% CI) 54.3 (42.4-64.7) 30.1 (21.9-38.8) DoR, months Median (95% CI) 23.5 (18.1-NA) 15.2 (10.2-19.2) HR (95% CI) 0.51 (0.33-0.79) P-value 0.0024 12-months DoR rate (95% CI) 77.7 (65.7-85.9) 55.8 (44.3-65.9) 24-months DoR rate (95% CI) 46.9 (33.7-59.0) 31.0 (20.9-41.6) ORR (95% CI), % 87.7 (78.5-93.9) 66.9 (58.2-74.8) OR (95% CI) 3.54 (1.64-7.64) P-value 0.0013 DCR (95% CI), % 98.8 (93.3-100.0) 89.5 (83.0-94.1) OR (95% CI) 9.59 (1.22-75.54) P-value 0.0318 DepOR, % Mean (Std) -50.5 (17.4) -42.0 (24.1) Range -100.0-3.6 -100.0-50.0 P-value 0.0105 Citation Format: Shun Lu, Chuan Li, Hong Jian, Xiaorong Dong, Jianhua Chen, Gongyan Chen, Yuping Sun, Yinghua Ji, Jiawei Wei, Si Sun, Zhenzhong Su, Qiu Sun, Hongying Wei, Qiong Wu. Elevated creatine phosphokinase (CPK) as a strong predictor of aumolertinib (Au) treatment response in patients (pts) with advanced non-small cell lung cancer (NSCLC): post-hoc analysis of AENEAS. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5462." @default.
• W4379984267 created "2023-06-10" @default.
• W4379984267 creator A5006148444 @default.
• W4379984267 creator A5016020113 @default.
• W4379984267 creator A5020140861 @default.
• W4379984267 creator A5032987311 @default.
• W4379984267 creator A5038778629 @default.
• W4379984267 creator A5047365416 @default.
• W4379984267 creator A5053141560 @default.
• W4379984267 creator A5053958450 @default.
• W4379984267 creator A5064280954 @default.
• W4379984267 creator A5075302079 @default.
• W4379984267 creator A5077703494 @default.
• W4379984267 creator A5083642725 @default.
• W4379984267 creator A5085701664 @default.
• W4379984267 creator A5090712753 @default.
• W4379984267 date "2023-04-04" @default.
• W4379984267 modified "2023-09-25" @default.
• W4379984267 title "Abstract 5462: Elevated creatine phosphokinase (CPK) as a strong predictor of aumolertinib (Au) treatment response in patients (pts) with advanced non-small cell lung cancer (NSCLC): post-hoc analysis of AENEAS" @default.
• W4379984267 doi "https://doi.org/10.1158/1538-7445.am2023-5462" @default.
• W4379984267 hasPublicationYear "2023" @default.
• W4379984267 type Work @default.
• W4379984267 citedByCount "0" @default.
• W4379984267 crossrefType "journal-article" @default.
• W4379984267 hasAuthorship W4379984267A5006148444 @default.
• W4379984267 hasAuthorship W4379984267A5016020113 @default.
• W4379984267 hasAuthorship W4379984267A5020140861 @default.
• W4379984267 hasAuthorship W4379984267A5032987311 @default.
• W4379984267 hasAuthorship W4379984267A5038778629 @default.
• W4379984267 hasAuthorship W4379984267A5047365416 @default.
• W4379984267 hasAuthorship W4379984267A5053141560 @default.
• W4379984267 hasAuthorship W4379984267A5053958450 @default.
• W4379984267 hasAuthorship W4379984267A5064280954 @default.
• W4379984267 hasAuthorship W4379984267A5075302079 @default.
• W4379984267 hasAuthorship W4379984267A5077703494 @default.
• W4379984267 hasAuthorship W4379984267A5083642725 @default.
• W4379984267 hasAuthorship W4379984267A5085701664 @default.
• W4379984267 hasAuthorship W4379984267A5090712753 @default.
• W4379984267 hasConcept C126322002 @default.
• W4379984267 hasConcept C143998085 @default.
• W4379984267 hasConcept C168563851 @default.
• W4379984267 hasConcept C203092338 @default.
• W4379984267 hasConcept C2776256026 @default.
• W4379984267 hasConcept C2780739268 @default.
• W4379984267 hasConcept C3019894029 @default.
• W4379984267 hasConcept C67761136 @default.
• W4379984267 hasConcept C71924100 @default.
• W4379984267 hasConcept C90924648 @default.
• W4379984267 hasConceptScore W4379984267C126322002 @default.
• W4379984267 hasConceptScore W4379984267C143998085 @default.
• W4379984267 hasConceptScore W4379984267C168563851 @default.
• W4379984267 hasConceptScore W4379984267C203092338 @default.
• W4379984267 hasConceptScore W4379984267C2776256026 @default.
• W4379984267 hasConceptScore W4379984267C2780739268 @default.
• W4379984267 hasConceptScore W4379984267C3019894029 @default.
• W4379984267 hasConceptScore W4379984267C67761136 @default.
• W4379984267 hasConceptScore W4379984267C71924100 @default.
• W4379984267 hasConceptScore W4379984267C90924648 @default.
• W4379984267 hasIssue "7_Supplement" @default.
• W4379984267 hasLocation W43799842671 @default.
• W4379984267 hasOpenAccess W4379984267 @default.
• W4379984267 hasPrimaryLocation W43799842671 @default.
• W4379984267 hasRelatedWork W1608269846 @default.
• W4379984267 hasRelatedWork W2081790265 @default.
• W4379984267 hasRelatedWork W2516942920 @default.
• W4379984267 hasRelatedWork W2723438097 @default.
• W4379984267 hasRelatedWork W2789668336 @default.
• W4379984267 hasRelatedWork W2891273047 @default.
• W4379984267 hasRelatedWork W2902679640 @default.
• W4379984267 hasRelatedWork W2904759734 @default.
• W4379984267 hasRelatedWork W4229043315 @default.
• W4379984267 hasRelatedWork W4285492859 @default.
• W4379984267 hasVolume "83" @default.
• W4379984267 isParatext "false" @default.
• W4379984267 isRetracted "false" @default.
• W4379984267 workType "article" @default.